Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17221781 | 0.71 | — | — | |
| SCHEMBL1681348 | 0.65 | — | — | |
| SCHEMBL17221840 | 0.65 | — | — | |
| SCHEMBL6342260 | 0.59 | — | — | |
| SCHEMBL363105 | 0.59 | — | — | |
| SCHEMBL28141919 | 0.58 | — | — | |
| SCHEMBL7006077 | 0.57 | — | — | |
| SCHEMBL28794876 | 0.57 | — | — | |
| SCHEMBL27883137 | 0.57 | PTPRC (0.44) | TSHR | |
| SCHEMBL9484675 | 0.56 | PTPRC (0.55) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772253-B2 | Amide derivatives as somatostatin receptor 5 antagonists | HOFFMAN-LA ROCHE INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7645753-B2 | Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| EP-1893603-B1 | PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2009-10-14 | — | — | EP | disclosed |
| EP-1858901-B1 | BENZOTHIAZOLE, THIAZOLOPYRIDINE, BENZOOXAZOLE AND OXAZOLOPYRIDINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2008-11-05 | — | — | EP | disclosed |
| EP-1893603-A1 | PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2008-03-05 | — | — | EP | disclosed |
| EP-1858901-A1 | BENZOTHIAZOLE, THIAZOLOPYRIDINE, BENZOOXAZOLE AND OXAZOLOPYRIDINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006128803-A1 | PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-07 | — | — | WO | disclosed |
| US-20060276508-A1 | Amide derivatives as somatostatin receptor 5 antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-07 | — | — | US | disclosed |
| WO-2006094682-A1 | BENZOTHIAZOLE, THIAZOLOPYRIDINE, BENZOOXAZOLE AND OXAZOLOPYRIDINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-14 | — | — | WO | disclosed |
| US-20060205718-A1 | Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276508-A1 | Amide derivatives as somatostatin receptor 5 antagonists | SSTR5, SSTR3, SSTR1 | TSHR 20/4885MAPK1 1831/4885 |
| US-20060205718-A1 | Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives | SSTR5, SSTR1, SSTR2 | TSHR 26/4885MAPK1 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.